替尔泊肽治疗2型糖尿病患者早期空腹血糖或体重下降与代谢结局:SURPASS试验的事后分析
本事后分析汇总SURPASS试验数据,按第4周空腹血糖下降<20%或≥20%、第8周体重下降<5%或≥5%定义早期应答者,评估第40/42周代谢结局。空腹血糖早期应答者(50%)与体重早期应答者(31%)的HbA1c和体重改善更优,胃肠道不良事件发生率与无早期应答者总体相当。
要点
- 空腹血糖早期应答者第40/42周HbA1c降幅-2.6% vs 无早期应答者-2.0%。
- 体重早期应答者第40/42周体重降幅-15% vs 无早期应答者-8%。
- 无早期应答者各替尔泊肽剂量下仍有临床意义的HbA1c和体重下降。
核心结论
- 替尔泊肽治疗中早期血糖应答和早期体重应答均与更好的长期代谢结局相关。
- 早期应答可能是有助于个体化治疗以达到治疗目标的良好临床指标。
研究设计与样本
- SURPASS试验的事后分析,汇总各试验数据。
- 空腹血糖分析纳入SURPASS-1至-4,n=3,676;体重分析纳入SURPASS-1至-5,n=4,121,分别为疗效和安全分析集。
- 按第4周空腹血糖下降<20%或≥20%、第8周体重下降<5%或≥5%定义早期应答者。
主要发现
- 空腹血糖早期应答者占50%,较年轻,基线血糖参数更高、体重更低。
- 体重早期应答者占31%,基线血糖参数和体重更低,女性和白人比例更高。
- 空腹血糖早期应答者 vs 无早期应答者第40/42周HbA1c降幅-2.6% vs -2.0%,体重降幅-11% vs -10%。
- 体重早期应答者 vs 无早期应答者第40/42周HbA1c降幅-2.5% vs -2.2%,体重降幅-15% vs -8%。
- 早期应答者血压和血脂谱改善更大;胃肠道不良事件(一般为轻至中度)发生率随时间下降,早期与无早期应答者总体相当。
临床怎么用
- 作者认为早期应答可能是良好的临床指标,有助于个体化治疗以达到治疗目标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate late (week 40 or 42; hereafter, week 40/42) metabolic outcomes by early glycemic response (<20% or ≥20% fasting serum glucose [FSG] reduction at week 4) or weight response (<5% or ≥5% weight reduction at week 8), respectively, in tirzepatide-treated participants with type 2 diabetes in the SURPASS trials. RESEARCH DESIGN AND METHODS: This post hoc analysis used pooled data across trials. Baseline characteristics, change from baseline to week 40/42 for efficacy parameters, and gastrointestinal (GI) adverse events (AEs) were described and analyzed by early response in terms of FSG (SURPASS-1 to -4; n = 3,676) or weight (SURPASS-1 to -5; n = 4,121) in the efficacy and safety analysis set, respectively. RESULTS: Early responders in FSG (50%) were younger, with higher glycemic parameters and lower weight at baseline. Early responders in weight (31%) had lower glycemic parameters and weight at baseline, and a greater percentage were women and White. Early versus nonearly responders in FSG or weight achieved better HbA1c (-2.6% vs. -2.0% or -2.5% vs. -2.2%, respectively) and weight (-11% vs. -10% or -15% vs. -8%, respectively) responses at week 40/42 and greater improvements in blood pressure and lipids profile. Nonearly responders also had clinically meaningful HbA1c and weight reductions with all tirzepatide doses. The incidence of GI AEs (generally mild to moderate events) decreased over time and was, in general, comparable between early and nonearly responders. CONCLUSIONS: Both early glucose and weight responses with tirzepatide were associated with better longer-term metabolic outcomes. Early response may be a good clinical indicator that could help inform treatment individualization to achieve therapeutic goals.
引用
- Giorgino F, Lingvay I, Van Gaal LF, et al. Early Fasting Serum Glucose or Weight Reduction With Tirzepatide and Metabolic Outcomes in People With Type 2 Diabetes: A Post Hoc Analysis of the SURPASS Trials. Diabetes Care. 2025. PMID: 40100982. doi:10.2337/dc24-2790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。